Chairman of ACRO Biomedical, Dr. Dar-Jen Hsieh, has years of experience in the biotechnology and healthcare field. He has held industrial, governmental, and academic positions.

His Philosophical Approach:

In the past thirty years, Taiwan has stumbled along the way to develop a viable biotechnology and pharmaceutical industry. Struggles of the past laid the foundation of what it is today. Whoever has passion and vision, industry insiders or not, should appreciate these hard-earned accomplishments and continue to work together to nurture this industry in Taiwan.

With R&D as its core, ACRO Biomedical is committed to long-term development of innovative products. Using the most environmentally friendly and cleanest technologies, ACRO Biomedical aims to develop a series of biomaterials for tissue and organ repairs as well as the next generation of regenerative medical products, which will combine drugs, peptides, growth factors, biologics, and even human stem cells with biomaterial scaffolds to further enhance organ and tissue repairs, ultimately improving healthcare and quality of life.